Lantheus (NASDAQ:LNTH) Posts Quarterly Earnings Results, Misses Estimates By $0.23 EPS

Lantheus (NASDAQ:LNTH) released its earnings results on Wednesday. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.23), Zacks reports. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. Lantheus updated its FY 2025 guidance to 7.000-7.200 EPS.

Lantheus Trading Up 16.4 %

Shares of LNTH stock traded up $13.13 on Wednesday, reaching $93.18. 1,697,576 shares of the company’s stock were exchanged, compared to its average volume of 851,706. Lantheus has a 52 week low of $56.44 and a 52 week high of $126.89. The stock has a market capitalization of $6.48 billion, a PE ratio of 15.53 and a beta of 0.44. The company’s fifty day simple moving average is $89.77 and its 200 day simple moving average is $96.81.

Insider Activity

In other Lantheus news, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the sale, the director now directly owns 33,207 shares of the company’s stock, valued at $3,146,695.32. The trade was a 2.92 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 1.50% of the company’s stock.

Analysts Set New Price Targets

LNTH has been the subject of a number of research analyst reports. The Goldman Sachs Group started coverage on shares of Lantheus in a report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective for the company. StockNews.com cut shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Truist Financial reiterated a “buy” rating and issued a $120.00 price target (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. Finally, JMP Securities restated a “market outperform” rating and set a $112.00 price objective on shares of Lantheus in a research report on Tuesday, January 14th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, Lantheus presently has an average rating of “Moderate Buy” and an average target price of $131.86.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.